PTC Therapeutics (NASDAQ:PTCT) Cut to "Hold" at Wall Street Zen
Wall Street Zen downgraded PTC Therapeutics (NASDAQ:PTCT) from "buy" to "hold" following a significant miss in Q4 earnings and weaker-than-expected FY-2026 revenue guidance. The company reported an EPS of ($1.67) against a consensus of ($0.21) and revenue of $164.7M versus $281.5M expected, with future revenue guidance set at $700-$800M compared to Street estimates of $974M. Despite insider selling, institutional investors like Vanguard and Janus Henderson Group have increased their stakes, creating mixed signals for investors.
Lee Scott Golden Sells 2,484 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock
Lee Scott Golden, an EVP at PTC Therapeutics (NASDAQ:PTCT), sold 2,484 shares of the company's stock on February 18th for approximately $172,290. This sale follows recent multiple insider sales by executives and occurred after the company reported a significant Q4 earnings and revenue miss and provided lower-than-expected FY2026 guidance. Despite the negative news, PTCT's stock traded up by 1.1% on Friday, and analysts maintain a "Moderate Buy" rating with a consensus price target of $80.73.
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CAO Sells 2,494 Shares of Stock
PTC Therapeutics' Chief Accounting Officer, Christine Marie Utter, sold 2,494 shares of her company's stock for approximately $173,000, reducing her stake by over 3%. This sale follows a cluster of insider selling by other executives and occurred shortly after the company announced a significant Q4 earnings and revenue miss, alongside lowered FY-2026 guidance. Despite the negative financial news and insider selling, the stock traded up slightly, and analysts maintain a "Moderate Buy" rating with a target price of $80.73.
PTC Therapeutics (NASDAQ:PTCT) CFO Pierre Gravier Sells 2,992 Shares
PTC Therapeutics' CFO, Pierre Gravier, sold 2,992 shares of the company's stock for approximately $207,525 on February 18th, reducing his stake by 3.31%. This insider sale follows a significant fourth-quarter earnings miss, where the company reported an EPS of ($1.67) against an estimated ($0.21) and revenue of $164.7 million versus a $281.5 million consensus, leading to lowered FY-2026 revenue guidance. Despite these financial setbacks and regulatory uncertainties, the company highlights strong early uptake of Sephience and a robust cash position of $1.95 billion to support future commercialization and R&D.
PTC’s Sephience Launch Appears Off To A Strong Start
PTC's new drug, Sephience, is showing strong initial sales performance. The company anticipates blockbuster status for the drug, based on its first five months of revenue. This success indicates a promising start for Sephience in the market.
PTC Therapeutics (NASDAQ:PTCT) Trading Down 6.5% on Disappointing Earnings
PTC Therapeutics (NASDAQ:PTCT) shares fell 6.5% after reporting disappointing Q4 earnings, missing consensus estimates significantly on both EPS and revenue. The company also issued weaker-than-expected revenue guidance for fiscal year 2026 and faces regulatory uncertainty, leading to negative investor sentiment. Despite these setbacks, strong uptake for its Sephience product, substantial cash reserves, and some analyst optimism provide potential offsets.
PTC Therapeutics Q4 2025 Financial Results: Loss, Revenue Shortfall - News and Statistics
PTC Therapeutics Inc. reported a significant loss of $135 million, or $1.67 per share, for the fourth quarter of 2025, falling short of analyst expectations of a 21-cent loss per share. The company's revenue of $164.7 million also missed forecasts of $304.7 million. Despite the quarterly shortfall, PTC Therapeutics recorded a full-year profit of $682.6 million, or $7.78 per share, on annual revenue of $1.73 billion.
PTC Therapeutics: Q4 Earnings Snapshot
PTC Therapeutics Inc. reported a significant loss of $135 million, or $1.67 per share, in its fourth quarter, falling short of Wall Street estimates. The biopharmaceutical company also missed revenue expectations, posting $164.7 million against an anticipated $304.7 million. For the full year, PTC Therapeutics reported a profit of $682.6 million on revenues of $1.73 billion.
PTC Therapeutics (NASDAQ:PTCT) VP Sells $194,912.77 in Stock
PTC Therapeutics VP Mark Elliott Boulding sold 2,813 shares of the company's stock for $194,912.77 on February 17th, decreasing his stake by 2.46%. This sale follows several other transactions by Boulding in recent months. The company recently reported a significant earnings miss, yet analysts maintain a "Moderate Buy" rating with an average target price of $80.67.
PTC Therapeutics: Fourth Quarter Financial Highlights
PTC Therapeutics reported a net loss of $135 million for the fourth quarter, resulting in a loss of $1.67 per share, significantly missing analyst expectations of a much smaller loss. The biopharmaceutical firm's revenue of $164.7 million also fell short of projections. For the full year, the company posted a profit of $682.6 million and total revenue of $1.73 billion.
PTC Therapeutics Tops 2025 Revenue Guidance, Boosts Cash
PTC Therapeutics exceeded its 2025 revenue guidance, achieving $831 million in product and royalty revenue, largely driven by the successful launch of Sephience and significant collaboration income. The company increased its cash reserves to $1.95 billion and outlined higher revenue targets for 2026, while advancing its neurology pipeline. Analysts view PTCT positively, with an Outperform rating from TipRanks' AI Analyst, Spark.
Earnings Flash (PTCT) PTC Therapeutics, Inc. Reports Q4 Revenue $164.7M, vs. FactSet Est of $279.5M
PTC Therapeutics, Inc. (PTCT) reported its Q4 revenue at $164.7 million, significantly below the FactSet estimate of $279.5 million. The company released these financial results on February 19, 2026, alongside other financial updates including a Q4 loss of $1.67 per share and a withdrawal of its NDA resubmission for Translarna.
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
PTC Therapeutics reported strong financial results for the fourth quarter and full year 2025, exceeding revenue guidance with $831 million in product and royalty revenue. The company saw strong uptake of its new product Sephience, generating $111 million in revenue since its launch, and ended the year with $1.95 billion in cash. PTC also announced a positive outlook for 2026, projecting total product revenue of $700 to $800 million, largely driven by Sephience.
PTC Therapeutics (PTCT) Reports Q4 Loss, Misses Revenue Estimates
PTC Therapeutics (PTCT) reported a Q4 loss of $1.67 per share, significantly missing the Zacks Consensus Estimate of a $0.21 loss, and also fell short on revenue expectations with $164.68 million against an estimated 45.96% higher figure. Despite surpassing EPS estimates three times in the last four quarters, the company's shares have declined by 9.3% year-to-date. The stock currently holds a Zacks Rank #3 (Hold) based on mixed estimate revisions.
Earnings Outlook For PTC Therapeutics
PTC Therapeutics (NASDAQ: PTCT) is scheduled to release its quarterly earnings report on Thursday, February 19, 2026, with analysts expecting an EPS of $-0.33. Investors will be keenly watching not only whether the company beats this estimate but also for positive guidance for the next quarter, as guidance often impacts stock price more than the earnings beat or miss itself. The company's previous EPS beat led to a share price increase, and its stock has shown a 37.92% gain over the last 52 weeks, indicating a positive sentiment among long-term shareholders ahead of this announcement.
PTC Therapeutics Faces Translarna Setback While Valuation Signals Potential Upside
PTC Therapeutics (NasdaqGS:PTCT) has withdrawn its New Drug Application resubmission for Translarna, a treatment for Duchenne muscular dystrophy, after unfavorable feedback from the FDA. This regulatory setback raises questions about the company's future pipeline and capital allocation, despite the stock appearing undervalued by analysts and Simply Wall St's own valuation. Investors are advised to monitor further updates on alternative regulatory paths and other pipeline assets.
Friedreich’s Ataxia Clinical Trial Pipeline Expands as 10+ Companies Progress 10+ Novel Therapies Toward Market Entry, Finds DelveInsight | PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx
DelveInsight's report indicates that over 10 companies are developing more than 10 novel therapies for Friedreich’s Ataxia, with several drugs, such as LX2006, RT001, and Leriglitazone (MIN-102), progressing through clinical stages. LX2006 received Breakthrough Therapy designation from the FDA, and its developers plan a pivotal study in the first half of 2026. This expansion reflects significant activity in addressing the unmet medical needs for Friedreich's Ataxia.
Friedreich’s Ataxia Clinical Trial Pipeline Expands as 10+ Companies Progress 10+ Novel Therapies Toward Market Entry, Finds DelveInsight | PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx
DelveInsight's "Friedreich’s Ataxia – Pipeline Insight, 2026" report reveals an expanding clinical trial pipeline for Friedreich's Ataxia, with over 10 companies advancing more than 10 novel therapies. Key players include PTC Therapeutics, Retrotope, Reata Pharmaceuticals, Minoryx Therapeutics, and others, with promising therapies like RT001 and Leriglitazone. The report highlights recent milestones, such as Lexeo Therapeutics' positive interim data for LX2006 and its Breakthrough Therapy designation from the FDA, indicating significant progress toward market entry for these treatments.
PTC pulls Translarna NDA after unfavourable FDA feedback
PTC Therapeutics has withdrawn its resubmitted New Drug Application (NDA) for Translarna, a Duchenne muscular dystrophy (DMD) therapy, following unfavorable feedback from the FDA regarding its efficacy data. This marks the third unsuccessful attempt by PTC to secure US approval for Translarna, which has also faced regulatory challenges in Europe. The drug's global sales are projected to decline significantly by 2031.
Ahead of PTC Therapeutics (PTCT) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Wall Street analysts anticipate PTC Therapeutics (PTCT) to report a quarterly loss of -$0.21 per share for Q4, an increase of 12.5% year-over-year, with revenues expected to hit $304.72 million, up 42.9%. Key metrics like net product revenue are projected at $174.53 million, royalty revenue at $70.77 million, while Translarna and Emflaza net product revenues are expected to decline. The company currently holds a Zacks Rank #3 (Hold), suggesting its stock performance will likely align with the broader market.
Why (PTCT) Price Action Is Critical for Tactical Trading
This article analyzes Ptc Therapeutics Inc. (NASDAQ: PTCT) using AI models, highlighting weak near and mid-term sentiment despite a long-term positive outlook. It presents specific trading strategies (Position, Momentum Breakout, Risk Hedging) with entry points, targets, and stop losses. The analysis also details multi-timeframe signal strengths and key support/resistance levels for tactical trading.
PTC Withdraws US FDA Filing For Translarna
PTC Therapeutics has withdrawn its New Drug Application (NDA) for Translarna from the US FDA, concluding a 12-year effort to secure approval for the drug in the United States. This decision comes despite previous attempts to appeal a Complete Response Letter and ongoing sales in the EU even after its marketing authorization was revoked there.
PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced it will host a webcast conference call on Thursday, February 19, 2026, at 4:30 p.m. ET to report its fourth quarter and full-year 2025 financial results. The company will also provide a business update and outlook during the call. A replay will be available on PTC's website for 30 days following the event.
PTC Therapeutics Ends Bid to Seek FDA Approval for Rare Muscle Disease Drug
PTC Therapeutics has withdrawn its application for FDA approval of Translarna, a Duchenne muscular dystrophy drug. The company cited irreconcilable differences with the FDA regarding the interpretation of clinical trial data, finding the efficacy data insufficient for approval. This decision follows a similar negative regulatory outcome in Europe last year, marking the end of a long effort to gain approval for the drug.
FDA skepticism ends PTC bid to market Duchenne drug Translarna in U.S.
PTC Therapeutics announced on February 12, 2026, the withdrawal of its New Drug Application (NDA) resubmission for Translarna (ataluren) for nonsense mutation Duchenne muscular dystrophy (DMD) in the U.S. This decision followed feedback from the FDA, which indicated that the submitted data were unlikely to meet the agency's threshold for substantial evidence of effectiveness to support approval. Despite over two decades of development, PTC's CEO expressed disappointment that FDA approval could not be achieved.
PTC Therapeutics Withdraws Translarna NDA After FDA Feedback
PTC Therapeutics (PTCT) has withdrawn its New Drug Application resubmission for Translarna, a therapy for Duchenne muscular dystrophy, after the FDA indicated insufficient evidence of effectiveness. This decision marks the end of a two-decade effort for U.S. approval, impacting patient access and the company’s market position. Despite this setback, TipRanks’ AI Analyst, Spark, rates PTCT as "Outperform" due to strong operating performance, cash generation, and positive commercial traction.
PTC Therapeutics falls after withdrawing muscle disorder drug marketing application
PTC Therapeutics (PTCT) saw its stock fall after the company withdrew its marketing application for a muscle disorder drug. The article indicates this news was reported by Reuters.
PTC Therapeutics (PTCT) Projected to Post Quarterly Earnings on Thursday
PTC Therapeutics (NASDAQ:PTCT) is scheduled to release its Q4 2025 earnings after market close on Thursday, February 19th, with analysts expecting a loss of $0.37 per share and revenue of $281.45 million. The stock is currently trading near its 52-week high, and insiders have been net sellers, offloading shares worth over $22.5 million in the last three months. Analysts maintain a "Moderate Buy" consensus rating with an average target price of $80.67.
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
PTC Therapeutics (PTCT) is expected to report a year-over-year increase in earnings and higher revenues for the quarter ended December 2025, with an earnings release anticipated on February 19. The company's Zacks Earnings ESP of +133.56% combined with a Zacks Rank of #3 suggests a high probability of beating consensus EPS estimates. Investors are advised to consider the Earnings ESP and Zacks Rank as strong indicators, although other factors can also influence stock performance.
PTC Therapeutics (NASDAQ:PTCT) Shareholders Have Earned a 18% CAGR Over the Last Three Years
PTC Therapeutics (NASDAQ:PTCT) shareholders have seen an 18% compound annual growth rate (CAGR) over the last three years, with the stock appreciating 63% in that period, although this trails the broader market return. The company recently became profitable, contributing to a 52% gain in the past year, indicating improved performance. Investors should look at the company's financial health and identified risk factors to understand long-term performance drivers.
PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU
PTC Therapeutics, Inc. (PTCT) has officially launched SUFIANCE for the treatment of Phenylketonuria (PKU). This new therapy aims to offer an innovative treatment option for patients affected by this genetic disorder, addressing unmet medical needs within the PKU community. The launch signifies a notable advancement in the therapeutic landscape for PKU management.
PTC Therapeutics, Inc. (PTCT) Launches SUFIANCE for PKU
The provided content is empty, so a summary cannot be generated.
PTC Therapeutics Inc (NASDAQ:PTCT): A GARP Stock with Strong Growth and Moderate Valuation
PTC Therapeutics Inc (NASDAQ:PTCT) has been identified as a "Growth at a Reasonable Price" (GARP) stock, demonstrating strong growth metrics alongside a moderate valuation. The biopharmaceutical company, specializing in rare disease treatments, shows significant revenue and earnings per share growth, with analysts predicting continued expansion. While its financial health and profitability exhibit some past inconsistencies, current indicators are deemed acceptable for supporting its growth trajectory.
PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026
PTC Therapeutics, Inc. announced that it will host a webcast conference call on Thursday, Feb. 19, 2026, at 4:30 p.m. ET, to report its fourth quarter and full year 2025 financial results. The company will also provide updates on its business and outlook during the call. Interested parties can access the call via phone registration or through the Investors section of PTC's website.
PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026
PTC Therapeutics, Inc. (NASDAQ: PTCT) announced it will host a webcast conference call to present its fourth quarter and full year 2025 financial results and business outlook. The event is scheduled for Thursday, February 19, 2026, at 4:30 p.m. ET. Investors can register for the call or access the webcast through the company's website.
PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026
PTC Therapeutics, Inc. announced that it will host a webcast conference call on Thursday, Feb. 19, 2026, at 4:30 p.m. ET to report its fourth quarter and full year 2025 financial results. The company will also provide an update on its business and outlook during the call. The webcast will be accessible through the Investors section of PTC's website.
Understanding Momentum Shifts in (PTCT)
This article analyzes momentum shifts for Ptc Therapeutics Inc. (NASDAQ: PTCT), highlighting weak near-term sentiment but strong long-term projections. It provides three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis and key findings regarding risk-reward setups.
WCM Investment Management LLC Acquires Shares of 147,065 PTC Therapeutics, Inc. $PTCT
WCM Investment Management LLC significantly increased its stake in PTC Therapeutics (NASDAQ:PTCT) during Q3, acquiring 147,065 shares valued at approximately $8.92 million. This move comes as analyst sentiment remains largely positive with a "Moderate Buy" consensus, despite recent insider selling totaling over $23 million. PTC Therapeutics also reported strong quarterly earnings, beating revenue and EPS expectations.
PTCT SEC Filings - Ptc Therapeutics 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to PTC Therapeutics' (PTCT) SEC filings, including annual 10-K reports, quarterly 10-Q statements, and 8-K reports on material events and insider trading forms. It highlights key financial information, regulatory approvals, and insider transaction details, augmented by AI-powered summaries for quick understanding. The page serves as a critical resource for investors and traders to track the biopharmaceutical company's financial performance, regulatory developments, and corporate activities.
PTC Therapeutics, Inc. (NASDAQ:PTCT) Given Average Rating of "Moderate Buy" by Analysts
PTC Therapeutics (NASDAQ:PTCT) has received an average analyst rating of "Moderate Buy" from 16 firms, with a consensus 12-month price target of $80.67. Insider activity shows sales of 291,016 shares valued at $23.05 million over the past three months, reducing some directors' holdings significantly. The company recently surpassed quarterly earnings and revenue expectations, but analysts predict a negative EPS for the current fiscal year.
Converging Analyst Upgrades on PTC’s Rare Disease Pipeline Might Change The Case For Investing In PTC Therapeutics (PTCT)
Barclays recently upgraded PTC Therapeutics (PTCT) to an Overweight rating, joining other brokers in their positive outlook on the company's rare disease pipeline, including therapies for Duchenne muscular dystrophy and AADC deficiency. While this boosts sentiment, the company still faces challenges such as high debt, negative equity, and significant insider selling. Despite these concerns, analysts and Simply Wall St's fair value estimates suggest the stock might be undervalued, though with a wide range of price expectations.
Converging Analyst Upgrades on PTC’s Rare Disease Pipeline Might Change The Case For Investing In PTC Therapeutics (PTCT)
Recent analyst upgrades by Barclays and other brokers for PTC Therapeutics (PTCT) signal growing optimism regarding the company's rare disease pipeline, including therapies for Duchenne muscular dystrophy and AADC deficiency. While these upgrades boost sentiment and could lead to sharper market reactions to news, the investment narrative still grapples with a complex balance sheet, uneven earnings, high debt, and insider selling. Investors are advised to consider multiple perspectives and conduct thorough research, as fair value estimates for PTCT shares vary widely.
PTC Therapeutics (PTCT) Sees Analyst Rating Upgrade to Overweigh
Barclays has upgraded its rating for PTC Therapeutics (PTCT) to Overweight from Equal-Weight, significantly raising its price target from $68.00 to $119.00. This upgrade, reflecting a 75% increase, suggests a positive future outlook for the biopharmaceutical company which focuses on developing medicines for rare disorders. Other analysts have also adjusted their ratings and price targets for PTCT, indicating evolving perspectives on the company's market position.
PTC Therapeutics stock initiated with Overweight rating at Barclays By Investing.com
Barclays has initiated coverage on PTC Therapeutics (NASDAQ:PTCT) with an Overweight rating and a price target of $119.00, citing the significant potential of its phenylketonuria (PKU) treatment, which could generate over $2 billion in peak sales. The firm highlighted that the market currently undervalues the PKU opportunity and the long-term growth prospects from Huntington's Disease (HD) treatments. This positive outlook follows PTC Therapeutics' strong unaudited fourth-quarter revenue for Sephience and its overall exceeding of 2025 revenue guidance, alongside recent regulatory approval in Japan for Sephience.
PTC Therapeutics stock initiated with Overweight rating at Barclays
Barclays has initiated coverage on PTC Therapeutics (NASDAQ:PTCT) with an Overweight rating and a price target of $119.00, citing the significant potential of its phenylketonuria (PKU) treatment, which could generate over $2 billion in peak sales. The research firm believes the market currently undervalues the PKU opportunity and sees Huntington’s Disease treatments as a potential long-term growth driver. This news comes alongside strong revenue growth for PTC Therapeutics and recent positive regulatory updates for its drug Sephience.
A Look At PTC Therapeutics (PTCT) Valuation After New 2026 Revenue Guidance And Morgan Stanley Support
PTC Therapeutics recently announced 2026 product revenue guidance of US$700-800 million, excluding royalties. The stock has seen significant momentum with a 62.0% 1-year total return, currently trading at US$75.25 against an analyst target of US$83.57. Simply Wall St's narrative suggests PTC is undervalued at $81.86, driven by a robust late-stage pipeline, but notes that this valuation could change if regulatory or pricing pressures impact key products.
A Look At PTC Therapeutics (PTCT) Valuation After New 2026 Revenue Guidance And Morgan Stanley Support
PTC Therapeutics (PTCT) recently provided 2026 product revenue guidance of US$700 million to US$800 million, excluding royalties. The stock has seen significant momentum, with a 62.0% one-year total shareholder return, and analysts currently view it as 8.1% undervalued with a fair value of $81.86, supported by a robust late-stage pipeline including two NDAs under FDA review.
A Look At PTC Therapeutics (PTCT) Valuation After New 2026 Revenue Guidance And Morgan Stanley Support
PTC Therapeutics (PTCT) recently issued 2026 product revenue guidance of US$700 million to US$800 million. Despite a strong stock performance, the company is still considered 8.1% undervalued with a fair value of $81.86, supported by a robust late-stage pipeline including two NDAs under FDA review. However, future performance could be impacted by factors like Sephience uptake and regulatory pressures.
Avoiding Lag: Real-Time Signals in (PTCT) Movement
This article analyzes Ptc Therapeutics Inc. (PTCT), indicating neutral near and mid-term readings but a positive long-term bias. It highlights a mid-channel oscillation pattern and an exceptional 46.7:1 risk-reward setup targeting a 13.3% gain against a 0.3% risk. The analysis also provides three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles and holding periods, along with multi-timeframe signal analysis.
Is PTC Therapeutics (PTCT) Still Attractive After A 65% One-Year Share Price Jump
PTC Therapeutics (PTCT) has seen a 64.9% share price increase over the last year. Despite this jump, a Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 60.6%, with an estimated intrinsic value of $193.49 per share against a current price of $76.17. Additionally, its current P/E ratio of 8.14x is below the Biotech industry average, further indicating it may be trading at a discount.
